Quiet on the insider front: nobody at NRX Pharmaceuticals, Inc. bought or sold NRXP shares on the open market this past year.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. On the institutional side, 47 funds reported holding NRXP at the end of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Javitt Jonathan C | Chair | Buy | 40,000 | $1.17 | $47K | SEC |
| Sep 11, 2023 | Gorovitz Aaron | Director | Buy | 35,000 | $0.32 | $11K | SEC |
| Sep 11, 2023 | Hurvitz Chaim | Director | Buy | 70,000 | $0.29 | $20K | SEC |
| Aug 24, 2023 | Javitt Jonathan C | Executive Officer | Buy | 100,000 | $0.33 | $33K | SEC |
| Aug 23, 2023 | Javitt Jonathan C | Executive Officer | Buy | 200,000 | $0.32 | $64K | SEC |
There were no open-market insider trades in NRXP in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
47 investment managers reported holding NRXP in SEC Form 13F filings for Q2 2026.
No congressional trades in NRXP were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).